These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34230555)

  • 21. Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells.
    Asano R; Kuroki Y; Honma S; Akabane M; Watanabe S; Mayuzumi S; Hiyamuta S; Kumagai I; Sode K
    MAbs; 2018; 10(6):854-863. PubMed ID: 29985753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. eIg-based bispecific T-cell engagers targeting EGFR: Format matters.
    Kühl L; Schäfer AK; Kraft S; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2023; 15(1):2183540. PubMed ID: 36864566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cloning, expression, purification and characterization of a bispecific single-chain diabody against fluoroquinolones and sulfonamides in Escherichia coli.
    Chen M; Wen K; Tao X; Xie J; Wang L; Li Y; Ding S; Jiang H
    Protein Expr Purif; 2014 Aug; 100():19-25. PubMed ID: 24816423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
    Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Construction and expression of an anti-EGFR/anti-KDR bispecific single-chain diabody].
    Zhou YQ; Zhang J; Jin HZ; He Y; Wang T; Wang M
    Yao Xue Xue Bao; 2012 Oct; 47(10):1317-22. PubMed ID: 23289143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells.
    Riccio G; Ricardo AR; Passariello M; Saraiva K; Rubino V; Cunnah P; Mertens N; De Lorenzo C
    J Immunother; 2019 Jan; 42(1):1-10. PubMed ID: 30520849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy.
    Kujawski M; Li L; Bhattacharya S; Wong P; Lee WH; Williams L; Li H; Chea J; Poku K; Bowles N; Vaidehi N; Yazaki P; Shively JE
    BMC Cancer; 2019 Sep; 19(1):882. PubMed ID: 31488104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.
    Mølgaard K; Compte M; Nuñez-Prado N; Harwood SL; Sanz L; Alvarez-Vallina L
    Gene Ther; 2017 Apr; 24(4):208-214. PubMed ID: 28075428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A tetravalent single chain diabody (CD40/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions.
    Lu L; Liu N; Fan K; Zhang G; Li C; Yan Y; Liu T; Fu WH
    Mol Immunol; 2019 May; 109():149-156. PubMed ID: 30951934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
    Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
    Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bispecific T-cell engagers for cancer immunotherapy.
    Huehls AM; Coupet TA; Sentman CL
    Immunol Cell Biol; 2015 Mar; 93(3):290-6. PubMed ID: 25367186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of salinomycin and lasalocid in chicken liver by icELISA based on functional bispecific single-chain antibody (scDb) and interpretation of molecular recognition mechanism.
    Chen Y; Zhao K; Huang J; Li M; Sun X; Li J
    Anal Bioanal Chem; 2021 Nov; 413(28):7031-7041. PubMed ID: 34661725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
    Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
    J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.
    Yamamoto K; Trad A; Baumgart A; Hüske L; Lorenzen I; Chalaris A; Grötzinger J; Dechow T; Scheller J; Rose-John S
    Biochem J; 2012 Jul; 445(1):135-44. PubMed ID: 22509934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.